Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

World Journal of Surgical Oncology 1/2012

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2012
Autoren:
Rong Biaoxue, Yang Shuanying, Li Wei, Zhang Wei, Ming Zongjuan
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-170) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Rong BX and Yang SY participated in the design and coordination of the study, carried out the critical appraisal of the studies, statistical analysis of the studies and wrote the manuscript. Li W, Zhang W, and Ming ZJ developed the literature search, carried out the extraction of data, assisted in the critical appraisal of included studies and assisted in writing up. All authors read and approved the final manuscript.

Abstract

Background

Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence.

Methods

Fifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.

Results

The overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05).

Conclusions

Endostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.
Zusatzmaterial
Authors’ original file for figure 1
12957_2012_1146_MOESM1_ESM.jpeg
Authors’ original file for figure 2
12957_2012_1146_MOESM2_ESM.jpeg
Authors’ original file for figure 3
12957_2012_1146_MOESM3_ESM.jpeg
Authors’ original file for figure 4
12957_2012_1146_MOESM4_ESM.jpeg
Authors’ original file for figure 5
12957_2012_1146_MOESM5_ESM.jpeg
Authors’ original file for figure 6
12957_2012_1146_MOESM6_ESM.jpeg
Authors’ original file for figure 7
12957_2012_1146_MOESM7_ESM.jpeg
Authors’ original file for figure 8
12957_2012_1146_MOESM8_ESM.jpeg
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Neu im Fachgebiet Chirurgie


 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise